Von der Leyen: no mention of biotechnology
In view of her confirmation as EU Commission President, biotech associations have reminded Ursula von der Leyen of her promise to strategically promote the sector with an EU Biotech Act 2025.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1300 entries already.
Entries by Thomas Gabrielczyk
Scientists prevent transplant rejection
/in News/by Thomas GabrielczykScientists at Hannover Medical School (MHH) have genetically engineered pig lungs in such a way that immunosuppressants could be reduced during transplants.
SOTIO partners with Biocytogen to expand ADC pipeline
/in News/by Thomas GabrielczykCzech Sotio Biotech has inked an R&D and licence option agreement with Chinese antibody maker Biocytogen.
Draupnir Bio ApS raises further equity
/in News/by Thomas GabrielczykTargeted protein degradation Draupnir Bio Aps has raised further €12m in an equitiy investment to advance its preclinical pipeline.
CordenPharma invests €900m in peptide patform expansion
/in News/by Thomas GabrielczykCordenPharma is making a record investment of about €900m over the next three years in expanding its peptide platform, both at its Colorado, US site and in Europe.
Catalym raises US$150m
/in News/by Thomas GabrielczykGerman cancer specialist Catalym GmbH has raised US$150m to finance proof-of-concept studies.
Sensorion achieves milestones in Phase II trial
/in News/by Thomas GabrielczykFrench Sensorion SA has reported new efficacy endpoints data from SENS-401 in a Phase II study for the preservation of residual hearing loss.
Rentschler doubles cGMP capacity
/in News/by Thomas GabrielczykIn the largest expansion in the company’s 150-year history, the Laupheim-headquartered CDMO Rentschler Biopharma SE has launched a new production line at its site in Milford, USA.
SciRhom GmbH closes €63m Series A financing
/in News/by Thomas GabrielczykGerman iRhom2-targeted antibody specialist SciRhom GmbH has closed an oversubscribed €63m Series A financing that will be used to provide clinical proof of concept in autoimmune disorders.
Ligand Pharma to acquire Apeiron Biologics
/in News/by Thomas GabrielczykAustrian Apeiron Biologics goes to Ligand Pharmaceuticals for US$100m.